SciELO - Scientific Electronic Library Online

 
vol.37 issue4Perception and satisfaction of main researchers on the management of a Clinical Research Ethics CommitteeEffectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

DAVIES, A. et al. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenous coronary intervention: a Spanish model-based cost-effectiveness analysis. Farm Hosp. [online]. 2013, vol.37, n.4, pp.307-316. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.4.687.

Objective: To assess the long-term cost-effectiveness of 12 months treatment of prasugrel compared to clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in the Spanish health care system. Methods: A Markov state transition model was developed to estimate health outcomes, quality adjusted life years (QALYs), life years (LY), and costs over patients' lifetimes. Clinical inputs were based on an analysis of the TRITON-TIMI 38 clinical trial. Hospital readmissions captured during the trial in a sub-study of patients from eight countries (and subsequent re-hospitalisations modelled to accrue beyond the time horizon of the trial), were assigned to Spanish diagnosis-related group payment schedules to estimate hospitalisation costs. Results: Mean total treatment costs were €11,427 and €10,910 for prasugrel and clopidogrel respectively. The mean cost of the study drug was €538 higher for prasugrel vs. clopidogrel, but rehospitalisation costs at 12 months were €79 lower for prasugrel due to reduced rates of revascularisation. Hospitalisation costs beyond 12 months were higher with prasugrel by €55, due to longer life expectancy (+0.071 LY and +0.054 QALYs) associated with the decreased nonfatal myocardial infarction rate in the prasugrel group. The incremental cost per life year and QALY gained with prasugrel was €7,198, and €9,489, respectively. Conclusion: Considering a willingness-to-pay threshold of €30,000/QALY gained in the Spanish setting, prasugrel represents a cost-effective option in comparison with clopidogrel among patients with ACS undergoing PCI.

Keywords : Cost-effectiveness; Prasugrel; Acute coronary syndrome; Spain.

        · abstract in Spanish     · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License